Are you looking for digital health solutions that are adopted by patients at the start of therapy and keeps them on the therapy for as long as it is necessary? Dive into the latest insights from Ypsomeds’ Human Factors studies on digital health solutions.

Innovative peptide hormone molecules for treating diabetes and obesity are fundamentally changing the market for self-injection systems and the demand for pens and autoinjectors continues to increase.

Christian Esser Wiesemann provides the latest insights into the YpsoDose pre-filled and pre-assembled patch injector which is available for clinical trials.

In our new blog “Ypsomed Pulse”, we want to share expertise and knowledge with our customers, partners, and other players in and around the industry because we believe in the benefit of collective growth and progress.

Immerse yourself in the future of subcutaneous drug administration with large-volume autoinjectors. Our comprehensive literature review reveals their transformative potential to break barriers in delivering single large-volume doses.

UnoPen and YpsoPen are two of Ypsomed’s platforms developed and customized on behalf of various pharma customers for patients dependent on insulin but also GLP-1, hGH, FSH and PTH. Demand for these devices has now exceeded the total of 100 million UnoPen and 10 million YpsoPen delivered units.